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Abstract
Background: Chagas disease, caused by the parasite Trypanosoma cruzi (T. cruzi), is the leading etiology of non-ischemic
heart disease worldwide, with Latin America bearing the majority of the burden. This substantial burden and the limitations
of current interventions have motivated efforts to develop a vaccine against T. cruzi.
Methodology/Principal Findings: We constructed a decision analytic Markov computer simulation model to assess the
potential economic value of a T. cruzi vaccine in Latin America from the societal perspective. Each simulation run calculated
the incremental cost-effectiveness ratio (ICER), or the cost per disability-adjusted life year (DALY) avoided, of vaccination.
Sensitivity analyses evaluated the impact of varying key model parameters such as vaccine cost (range: $0.50–$200), vaccine
efficacy (range: 25%–75%), the cost of acute-phase drug treatment (range: $10–$150 to account for variations in acute-
phase treatment regimens), and risk of infection (range: 1%–20%). Additional analyses determined the incremental cost of
vaccinating an individual and the cost per averted congestive heart failure case. Vaccination was considered highly cost-
effective when the ICER was #1 times the GDP/capita, still cost-effective when the ICER was between 1 and 3 times the
GDP/capita, and not cost-effective when the ICER was .3 times the GDP/capita. Our results showed vaccination to be very
cost-effective and often economically dominant (i.e., saving costs as well providing health benefits) for a wide range of
scenarios, e.g., even when risk of infection was as low as 1% and vaccine efficacy was as low as 25%. Vaccinating an
individual could likely provide net cost savings that rise substantially as risk of infection or vaccine efficacy increase.
Conclusions/Significance: Results indicate that a T. cruzi vaccine could provide substantial economic benefit, depending on
the cost of the vaccine, and support continued efforts to develop a human vaccine.
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Introduction
Chagas disease (American trypanosomiasis), caused by the
parasite Trypanosoma cruzi (T. cruzi), is a leading etiology of non-
ischemic heart disease worldwide [1] and has a substantial impact
on Latin America, resulting in an estimated 750,000 productive
life years lost and 1.2 billion dollars lost annually [2,3,4]. Chagas
disease has three established phases: acute, indeterminate, and
chronic. While acute disease is primarily asymptomatic, cases
often transition to the chronic phase and clinically manifest as
cardiomyopathy and subsequent congestive heart failure (CHF)
decades after infection [1,5,6]. Furthermore, those who develop
Chagas-related CHF have poorer prognoses and higher mortality
rates than those with other CHF etiologies [2].
The substantial burden of Chagas disease and the limitations of
current interventions have motivated efforts to develop a vaccine
against T. cruzi. Although currently available drugs (benznidazole
and nifurtimox) are moderately efficacious when administered
during the acute phase, they have been minimally successful in
treating chronic infection [7,8,9]. Low rates of symptomatic acute
illness limit the utilization (and thus, the benefit) of these drugs
[5,8]. The lack of an available vaccine has left insecticide spraying
for T. cruzi vectors (reduvidae insects) as the primary control
strategy. However, implementing successful mass spraying can be
challenging [10,11]. Mass spraying requires both repeated and
consistent reapplication, which in turn necessitates funding,
personnel, and equipment. Due to a lack of national-level funding,
local communities may not have the resources to maintain
spraying. Furthermore, increased use of insecticides has elicited
resistance among vectors in Argentina and Bolivia and may lead to
untoward health effects for humans [11].
Several T. cruzi vaccine candidates have demonstrated protec-
tive effects against challenge in mouse models and offer promise
for the future development of a human vaccine [12,13]. Much
attention has focused on DNA vaccines, consisting of one or more
antigen-coding plasmids, which may provide sufficient protection
without the possibility of reverting back to the infectious form [12].
Understanding the potential economic and health benefits of a
T. cruzi vaccine could help guide vaccine investment, development,
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targeting, and implementation, thereby assisting vaccine scientists,
manufacturers, policy makers, and other decision makers. It can
be helpful to construct economic models early in a vaccine’s
development, before key decisions about the vaccine are made and
while important aspects of the vaccine can still be altered [14]. We
developed a computer model to evaluate the economic value of a
T. cruzi vaccine for the control of Chagas disease in Latin America.
Different scenarios helped determine the effects of varying various
key vaccine characteristics such as vaccine efficacy (to guide
development), vaccine cost (to help set future price points), and risk
of infection (to identify appropriate target populations).
Methods
Model Structure
We constructed a Markov decision analytic computer simula-
tion model to assess the potential cost-effectiveness of a T. cruzi
vaccine in Latin America using TreeAge Pro 2009 (TreeAge
Software, Williamstown, Massachusetts). The model assumed the
societal perspective and evaluated the economic value of
vaccination versus no vaccination of a cohort of children ,1 year
of age to prevent T. cruzi infection and Chagas disease. Each cycle
length was one year. Figure 1 illustrates the general model
structure, including the following six Markov states of the disease
model and an individual’s possible transitions between states:
N Susceptible/Well: The individual was healthy and uninfected
during this year.
N Acute Phase: The individual was actually infected with T. cruzi.
Infected individuals only remain in this state for 1 year.
N Indeterminate Phase: The latent phase of disease subsequent
to the acute phase. Those who became infected could remain
here for 10 years or more before transitioning to a chronic
form of Chagas disease, or could have remained in this phase
for life.
N Chronic Cardiomyopathy without CHF: Cardiac abnormali-
ties existed, but CHF had not developed. Cases that entered
into this state then had an annual probability of progressing to
CHF.
N Chronic Cardiomyopathy with CHF: Individual had CHF.
N Death: Death occurred as a result of either Chagas disease
(acute or chronic) or other causes unrelated to T. cruzi
infection.
All Markov states were mutually exclusive. Individuals entered the
model at age 0 and began in the ‘Susceptible/Well’ state (i.e., well
with no prior history of infection). Each passing year, the individual
either remained in the same state or transitioned to another state. The
individual continued in the model until he or she entered the Death
state from (1) acute/symptomatic infection, (2) cardiomyopathy with
or without CHF, or (3) mortality unrelated to T. cruzi infection, where
they remained for the remainder of the trial [5,6].
Figure 2a–e shows the possible paths an individual could have
traveled through after entering each Markov state. After entering
the ‘Susceptible/Well’ state, an individual had probabilities of
becoming infected (symptomatic or asymptomatic infection), dying
of unrelated causes, or remaining uninfected. Only symptomatic
cases had a probability of seeking T. cruzi treatment during the
acute phase. Consistent with standard medical operating proce-
dure, developing severe side effects resulted in discontinuation of
drug treatment and therefore eliminating any chance the
treatment could be successful. Asymptomatic cases did not receive
treatment and proceeded directly to the indeterminate (latent)
disease phase. The reported time from acute illness to develop-
ment of chronic cardiac manifestations in the literature ranged
from 10 to 30 years; infected individuals in the model therefore
had to stay in the indeterminate phase for at least 10 cycles (years)
before having an annual probability of developing cardiomyop-
athy (with or without CHF) [5,6,15,16,17]. Those who sought a
form of treatment for chronic infection once continued to do so
throughout the remainder of their life span.
Each simulation run sent 1,000 individuals through the model
1,000 times each for a total of 1,000,000 individual realizations.
For each simulation run, the following equation computed the
incremental cost-effectiveness ratio (ICER), or cost per disability-
adjusted life year (DALY) avoided, through vaccination:
ICER~
Cost Vaccine{Cost No Vaccine
{ DALYs Vaccine{DALYs No Vaccineð Þ
Quantification of DALY decrements for vaccinating and not
vaccinating included the years lost due to disability from Chagas
(YLD) as well as the years of life lost as a result of Chagas-related
mortality (YLL). Costs included both direct and indirect costs
(such as productivity loss) that resulted from becoming a Chagas
case. The cost-effectiveness of vaccination for each scenario was
evaluated using the GDP per capita of Colombia ($5,048.41), as it
represented the approximate average GDP per capita for all of
Latin America [18,19]. Vaccination was considered highly cost-
effective if the ICER value was $5,048.41 per DALY avoided or
less. Scenarios that yielded an ICER of $15,145.23 per DALY (3
times the GDP per capita) avoided or less still indicated that
vaccination was cost-effective, while ICERs greater than 3 times
the GDP per capita indicated that vaccination was not a cost-
effective strategy. The cost of vaccinating an individual was
calculated by comparing the average cost accrued on the vaccine
arm of the model to the average cost accrued on the no vaccine
arm over the 1 million trials for each simulation. The cost per
avoided congestive heart failure (CHF) case was calculated by
dividing the cost difference between the vaccine and no vaccine
arm for the entire cohort by the total number of CHF cases
Author Summary
The substantial burden of Chagas disease, especially in
Latin America, and the limitations of currently available
treatment and control strategies have motivated the
development of a Trypanosoma cruzi (T. cruzi) vaccine.
Evaluating a vaccine’s potential economic value early in its
development can answer important questions while the
vaccine’s key characteristics (e.g., vaccine efficacy targets,
price points, and target population) can still be altered.
This can assist vaccine scientists, manufacturers, policy
makers, and other decision makers in the development
and implementation of the vaccine. We developed a
computational economic model to determine the cost-
effectiveness of introducing a T. cruzi vaccine in Latin
America. Our results showed vaccination to be very cost-
effective, in many cases providing both cost savings and
health benefits, even at low infection risk and vaccine
efficacy. Moreover, our study suggests that a vaccine may
actually ‘‘pay for itself’’, as even a relatively higher priced
vaccine will generate net cost savings for a purchaser (e.g.,
a country’s ministry of health). These findings support
continued investments in and efforts toward the develop-
ment of a human T. cruzi vaccine.
Economics Chagas Disease Vaccine
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avoided on the vaccine arm/branch (compared to the no vaccine
branch) for the simulation.
Data Inputs
Table 1 shows the cost, probability, and DALY model input
values and their corresponding sources. The probability of an acute
case being symptomatic in the model was 1%. Based on a report of
treatment-seeking behavior for febrile illness, the probability that a
symptomatic individual sought treatment was 34% [5,8,20]. For
treatment costs, life expectancy, and crude mortality rates, data
from Colombia, where Chagas prevalence is high, served as a proxy
for Latin America [19].World Health Organization (WHO) sources
provided disability weights for cardiomyopathy with and without
CHF as well as crude mortality rates (0–11 mos, 1.65%; 1–4 yrs,
0.32%; 5–9 yrs, 0.15%; 10–14 yrs, 0.18%; 15–19 yrs, 0.55%; 20–
24 yrs, 0.97%; 25–29 yrs, 1.08%; 30–34 yrs, 1.02%; 35–39 yrs,
1.02%; 40–44 yrs, 1.12%; 45–49 yrs, 1.58%; 50–54 yrs, 2.11%;
55–59 yrs, 3.12%; 60–64 yrs, 4.99%; 65–69 yrs, 9.07%; 70–74 yrs,
14.66%; 75–79 yrs, 23.85%; 80–84 yrs, 30.62%; 85–89 yrs,
40.46%; 90–94 yrs, 51.70%; 95–99 yrs, 64.50%; 100 yrs and
older, 100%) and life expectancies (0–11 mos, 75.5 yrs; 1–4 yrs,
75.8 yrs; 5–9 yrs, 72 yrs; 10–14 yrs, 67.1 yrs; 15–19 yrs, 62.2 yrs;
20–24 yrs, 57.5 yrs; 25–29 yrs, 53.1 yrs; 30–34 yrs, 48.6 yrs; 35–
39 yrs, 44.1 yrs; 40–44 yrs, 39.5 yrs; 45–49 yrs, 35 yrs; 50–54 yrs,
30.4 yrs; 55–59 yrs, 26 yrs; 60–64 yrs, 21.8 yrs; 65–69 yrs,
17.8 yrs; 70–74 yrs, 14.3 yrs; 75–79 yrs, 11.4 yrs; 80–84 yrs,
Figure 1. Model Markov states. * Arrows represent states where Chagas-related death could occur. Non-Chagas-related death could occur during
any state.
doi:10.1371/journal.pntd.0000916.g001
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9.2 yrs; 85–89 yrs, 7.1 yrs; 90–94 yrs, 5.2 yrs; 95–99 yrs, 3.6 yrs;
100 yrs and older, 2.5yrs) [21,22].
Sensitivity Analyses
Sensitivity analyses evaluated the impact of varying key model
parameters such as vaccine cost (ranging from a low of $0.50 up to
the cost at which the vaccine was no longer cost-effective), vaccine
efficacy in preventing infection (range: 25% to 75%), the cost of
acute-phase drug treatment (range: $10–$150 to account for
variations in acute-phase treatment regimens), and risk of infection
(range: 1%–20%) [23]. As many studies report a cost associated
with routine surveillance (i.e., clinic visits, radiographs, electro-
cardiograms, and laboratory tests) during the indeterminate phase,
additional sensitivity analyses varied the probability that an
individual accrued a cost while in this phase from 25%–75%
[6,24]. Probabilistic sensitivity analyses determined the effects of
simultaneously varying parameter values across their respective
ranges.
Results
Overall Impact
Results suggest that a T. cruzi vaccine would be cost-effective
across a wide range of vaccine prices and efficacies and T. cruzi
infection risks. In fact, in many cases, a T. cruzi vaccine could
actually save costs (i.e., that would be associated with treating the
disease) in addition to providing health benefits. Vaccination
remained cost-effective even up to a vaccine price of $75 when
infection risk was 5% and vaccine efficacy was greater than 50%
and up to a vaccine price of $200 when the vaccine efficacy was
75% or greater.
Cost-Effectiveness
The majority of our modeled scenarios demonstrated vaccination
to be very cost-effective, and in many cases highly cost-effective,
especially with lower vaccine price points, compared to no
vaccination. Table 2 indicates the incremental cost-effectiveness
ratio (ICER) of Chagas vaccination at various vaccine costs,
infection risks and vaccine efficacy rates.When the total vaccine cost
was less than $5, vaccination was highly cost-effective across all
scenarios of infection risk (1%, 5%, 10% and 20%) and vaccine
efficacy (25%, 50%, and 75%). Increasing the vaccine price to $10
alters the vaccine strategy to cost-effective across all scenarios, and
finally when the vaccine cost is $20 and vaccine efficacy is 25%,
some scenarios become cost-ineffective. However, when the vaccine
efficacy is greater than 50%, vaccination remains cost-effective until
a $50 vaccine price point at 1% infection rate, a $75 vaccine price
point at 5% infection rate, and a $100 vaccine price point at 10%
infection rate. Vaccination remains cost-effective at a $200 price
point when the efficacy is greater than 50% and infection risk is
20%. The model was fairly robust and displayed minimal sensitivity
to variation in treatment costs for acute infection and the probability
of an indeterminate phase-associated cost.
Budget Impact Analysis
Table 3 shows that vaccinating an individual can actually be
cost savings under many explored circumstances. Negative values
in the table indicate that vaccinating an individual resulted in cost
savings (i.e., there was actually net monetary gain from vaccinating
an individual). For example, when a $1 vaccine was only 25%
efficacious and the risk of infection was 1%, vaccinating an
individual would on average save $1.52. At infection rates as low
as 1%, vaccination was cost-saving up to a $5 vaccine price point
as long as the vaccine remained at least 50% efficacious, with
savings overall ranging from 2$0.07 to 2$81.26 per vaccinated
individual. Vaccination remained cost-saving for all scenarios
under a $10 vaccine price point, when the risk of infection was 5%
or greater, averting the most cost (2$81) per vaccinee when
vaccine price was $1, efficacy was 75%, and infection risk was
20%. Administering vaccine only resulted in net cost ($2.44–$7.26)
at low infection risk (1%) and vaccine price point of $10 for the
entire range of evaluated vaccine efficacies. The cost benefit
persisted when the vaccine efficacy was 50% at vaccine costs of
$20–$30 when infection risk was greater of equal to 10%. When
the vaccine was 75% efficacious, a cost savings exists for vaccine
Table 1. Model inputs.
Variable
Baseline
Value Source
PROBABILITIES
Benznidazole Cure Rate Acute Phase 0.65a [5,26,28]
Drug Side Effects 0.05 [28]
Mortality Acute Phase 0.05b [5,6]
Annual Rate of Progression to Chronic
Phase
0.02 [15]
Cardiomyopathy 0.25c [5]
Seek Treatment if Cardiomyopathy 0.35 [6]
CHF if Cardiomyopathy 0.04 [6]
Mortality CHF 0.30 [6]
Mortality No CHF 0.04 [6]
DISABILITY WEIGHTS
Cardiomyopathy CHF 0.27 [22]
Cardiomyopathy No CHF 0.06 [22]
COSTS (US$)
Palliative Care Only CHFd 42 [16]
Palliative Care Only No CHF 23 [16]
Basic Care CHFe 61 [16]
Basic Care No CHFf 55 [16]
Intermediate Care CHFg 310 [16]
Intermediate Care No CHF 224 [16]
Specialized Care CHFh 9,530 [16]
Specialized Care No CHF 4,360 [16]
Indeterminate Phase 105 [6]
aUniform distribution with a lower limit of 0.5 and an upper limit of 0.8.
bTriangular distribution with a lower limit of 0.01 and an upper limit of 0.1.
cUniform distribution with a lower limit of 0.2 and an upper limit of 0.3.
dRefers to cases only seeking care to minimize their symptoms, not to prevent
or delay progression of disease.
eConsisted of 3 general practitioner visits and 0.58 days in the hospital.
fConsisted of 5.53 general practitioner visits and 0.25 days in the hospital.
gIncluded outpatient visits, diagnostics, medicine, and hospitalization costs.
hIncluded outpatient care, hospitalization, and hospital procedures such as
electrocardiography, x-rays, and surgery.
doi:10.1371/journal.pntd.0000916.t001
Figure 2. Markov state subtrees. A) Susceptible/Well B) Acute Phase C) Indeterminate Phase D) Cardiomyopathy with CHF E) Cardiomyopathy
without CHF. * Death resulting from Chagas infection ** Death from non-Chagas related causes.
doi:10.1371/journal.pntd.0000916.g002
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prices of #$50. For a vaccine cost of $200, the incremental cost of
vaccinating an individual ranged from $111.03 (20% infection
rate, 75% vaccine efficacy) to $197.36 (1% infection rate, 25%
vaccine efficacy).
Cost per CHF Case Averted
Table 4 displays the cost per CHF case averted by vaccination.
As can be seen, since the vaccine in most cases is cost savings, there
is actually net savings per CHF case averted. The greatest cost
Table 2. The incremental cost-effectiveness ratio (ICER) of
Chagas vaccination in US dollars.
Risk of T. cruzi Infection
Vaccine
Efficacy 1% 5% 10% 20%
Vaccine Cost = $0.50
25% Vaccinate Vaccinate Vaccinate Vaccinate
50% Vaccinate Vaccinate Vaccinate Vaccinate
75% Vaccinate Vaccinate Vaccinate Vaccinate
Vaccine Cost = $1
25% Vaccinate Vaccinate Vaccinate Vaccinate
50% Vaccinate Vaccinate Vaccinate Vaccinate
75% Vaccinate Vaccinate Vaccinate Vaccinate
Vaccine Cost = $5
25% 1,335 Vaccinate Vaccinate Vaccinate
50% Vaccinate Vaccinate Vaccinate Vaccinate
75% Vaccinate Vaccinate Vaccinate Vaccinate
Vaccine Cost = $10
25% 5,485 2,526 Vaccinate Vaccinate
50% 1,331 Vaccinate Vaccinate 7,178
75% 800 Vaccinate Vaccinate Vaccinate
Vaccine Cost = $20
25% 10,111 1,208 Don’t
Vaccinate
1,143
50% 7,541 205 Vaccinate Vaccinate
75% 5,629 Vaccinate Vaccinate Vaccinate
Vaccine Cost = $30
25% Don’t
Vaccinate
5,358 1,520 6,967
50% 10,849 746 Vaccinate Vaccinate
75% 8,987 Vaccinate Vaccinate Vaccinate
Vaccine Cost = $50
25% Don’t
Vaccinate
21,787 30,651 5,031
50% 23,012 3,201 1,007 898
75% 21,234 1,319 Vaccinate Vaccinate
Vaccine Cost = $75
25% 221,657 35,065 14,051 17,806
50% 26,492 14,614 4,097 5,316
75% 55,203 6,872 713 176
Vaccine Cost = $100
25% Don’t
Vaccinate
45,307 46,693 34,017
50% 450,040 36,600 8,757 5,263
75% 20,639 3,091 4,452 3,875
Vaccine Cost = $200
25% 122,109 71,062 26,972 36,640
50% Don’t
Vaccinate
58,412 50,385 8,743
75% 46,471 12,536 8,247 5,485
Bold numbers indicate a cost-effective strategy.
doi:10.1371/journal.pntd.0000916.t002
Table 3. The incremental cost of vaccinating an individual
($US).
Risk of T. cruzi Infection
Vaccine
Efficacy 1% 5% 10% 20%
Vaccine Cost = $1
25% 21.52 29.26 215.61 218.49
50% 24.29 221.92 231.24 250.02
75% 27.10 238.07 255.04 281.26
Vaccine Cost = $5
25% 2.21 25.99 210.78 215.65
50% 20.07 216.47 233.73 240.88
75% 24.08 231.31 254.09 278.27
Vaccine Cost = $10
25% 7.26 20.94 27.21 210.45
50% 4.54 212.97 228.66 236.90
75% 2.44 226.71 251.38 276.66
Vaccine Cost = $20
25% 17.53 10.28 3.73 1.98
50% 15.47 1.18 213.28 222.20
75% 13.02 211.52 233.08 254.50
Vaccine Cost = $30
25% 27.57 21.37 13.99 11.96
50% 25.80 10.54 23.23 210.45
75% 23.35 22.58 220.68 248.44
Vaccine Cost = $50
25% 47.52 40.78 36.18 7.96
50% 45.10 28.77 17.91 33.27
75% 42.54 17.79 21.28 224.04
Vaccine Cost = $75
25% 72.91 64.70 60.51 55.47
50% 70.64 54.00 43.79 31.81
75% 68.30 43.62 20.78 3.45
Vaccine Cost = $100
25% 97.50 90.26 84.13 81.40
50% 95.58 80.67 68.17 60.08
75% 93.37 67.85 45.09 28.40
Vaccine Cost = $200
25% 197.36 190.82 184.64 181.15
50% 194.71 180.03 165.09 154.43
75% 193.28 166.69 148.32 111.03
Incremental costs refer to the difference between the cost of vaccinating and
the cost of not vaccinating. Negative values indicate net cost savings with
vaccination; positive values indicate net costs with vaccination.
doi:10.1371/journal.pntd.0000916.t003
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savings per CHF case avoided were seen at the lowest vaccine cost
($1) and the lowest infection rates (1%). Under every scenario with
a vaccine cost of #$10 (regardless of indeterminate phase-cost
association or vaccine efficacy) and infection rates of 5% or above,
the cost per CHF case averted was negative, indicating a cost
savings per case avoided through vaccination. When infection
rates were 1% and vaccine cost increased to $10, the cost per
avoided CHF case was $50, 883 at 75% vaccine efficacy. At lower
efficacies (50% and 25%), cost per CHF case averted increased to
$126,009 and $660,350, respectively. At a vaccine price point of
$5, vaccinating to prevent a case of CHF ranged from costing over
$100,000 to saving over $100,000, depending on vaccine efficacy.
Discussion
Our results support further development and future implemen-
tation of a T. cruzi vaccine and have several implications for
vaccine policy makers, developers, and manufacturers. A T. cruzi
vaccine could not only decrease infection burden, but also severe
cardiac disease in Latin America. Our results suggest that
vaccination would be highly cost-effective (and in some cases,
economically dominant) over a wide range of infection rates,
treatment-seeking behaviors, and vaccine costs. Such findings
imply that vaccination may be beneficial even in areas with low
risk of infection or in endemic areas that are improving (i.e.,
decreasing infection risk) over time. Demonstrating that the
vaccine could provide net cost savings even at relatively higher
vaccine price points (such as $50) could encourage manufacturers
to pursue development and eventual commercialization of the
vaccine. Additionally, as our analysis suggests that the target
efficacy window for a vaccine can be fairly wide; scientists do not
necessarily have to design the near ‘‘perfect’’ vaccine that confers
protection close to 100% in order to establish economic value.
Even vaccines that offer lower levels of protection can be valuable,
especially at lower vaccine prices. Moreover, our study suggests
that a T. cruzi vaccine may actually ‘‘pay for itself’’: even a
relatively higher priced vaccine of $50 can generate net cost
savings for a purchaser (e.g., a country’s ministry of health).
As our results demonstrate, vaccine price helps drive the net
costs and cost-effectiveness of a T. cruzi vaccine. A vaccine that
costs $30 or less is cost-effective under most explored conditions.
However, a vaccine that costs $100 or more is cost-effective under
a much more limited set of circumstances. Our results may help
decision-makers map out the appropriate prices for a given
situation.
A T. cruzi vaccine could affect the epidemiology of cardiac
disease in endemic populations and countries. As management of
cardiomyopathy and CHF are associated with intensive and costly
medical care, preventing such outcomes would likely alleviate a
substantial burden on the healthcare system. A study conducted by
Mendez et al. reported that 20% of all cardiovascular disease
patients seen in a particular Brazilian health institution had
Chagas-related cardiomyopathy, and suggests that unresolved
Chagas infection accounts for nearly 30% of all CHF cases in
Brazil [25]. Additional literature suggests that a similar proportion
of CHF cases (20%) in Colombia result from Chagas disease [2].
Chagas disease may play an even larger role in causing cardiac
disease in other parts of Latin America.
Limitations of current alternatives have spurred efforts to
develop a T. cruzi vaccine. Although drugs exist for the treatment
of Chagas disease, they have many complications and are
associated with long treatment regimens and low cure rates when
administered after the acute disease phase [26]. DNA vaccines
have recently shown promise against several protozoan parasitic
diseases, such as malaria, leishmaniasis, and Chagas disease, as
they have proven to be safe and elicit a complete immune
response. Furthermore, their thermo-stability and affordability
may make them highly practical for use in resource poor settings
where these diseases are endemic. While this technology has yet to
yield an efficacious Chagas vaccine for the human population, the
development and licensure of DNA vaccines against West Nile and
infectious hematopoietic necrosis viruses in animals give promise
for a future human vaccine [12]. Certainly bringing a T. cruzi
Table 4. The cost per avoided case of congestive heart failure
(CHF) ($US).
Risk of T. cruzi Infection
Vaccine
Efficacy 1% 5% 10% 20%
Vaccine Cost = $1
25% 2108,779 2132,304 2130,069 281,435
50% 2195,117 2171,231 2135,221 2100,237
75% 2154,287 2186,595 2152,040 2115,263
Vaccine Cost = $5
25% 234,280 2117,542 291,333 266,319
50% 22,743 2145,784 2156,898 296,642
75% 2110,259 2166,543 2146,197 2110,397
Vaccine Cost = $10
25% 660,350 219,480 263,273 241,302
50% 126,009 2102,932 2118,409 278,352
75% 50,883 2157,108 2138,875 2108,278
Vaccine Cost = $20
25% 1,252,352 151,155 31,876 8,486
50% 967,156 10,071 257,757 244,047
75% 419,868 261,587 293,459 272,470
Vaccine Cost = $30
25% 2,121,101 403,277 123,817 41,973
50% 1,032,053 83,686 213,118 220,900
75% 631,111 213,236 257,275 269,105
Vaccine Cost = $50
25% 4,751,919 608,643 282,693 18,599
50% 1,503,296 241,724 74,020 149,209
75% 1,519,255 102,249 23,714 233,620
Vaccine Cost = $75
25% 4,860,652 1,043,606 521,635 224,576
50% 3,360,131 409,098 207,532 58,802
75% 1,751,278 241,000 55,279 4,612
Vaccine Cost = $100
25% 8,863,707 1,920,387 657,249 347,864
50% 3,540,061 783,224 333,905 129,760
75% 2,593,484 387,727 122,528 40,520
Vaccine Cost = $200
25% 14,097,245 2,981,599 1,538,697 846,508
50% 8,465,638 1,636,654 657,726 307,633
75% 5,368,789 963,519 429,911 170,284
Negative values indicate net cost savings with vaccination; positive values
indicate net costs with vaccination.
doi:10.1371/journal.pntd.0000916.t004
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vaccine to market would involve surmounting a variety of scientific
hurdles, but our study suggests that surmounting such obstacles
could be very worthwhile [12].
In developing our model, we attempted to remain conservative
about the benefits of a vaccine. The actual costs of diagnosing and
treating CHF may be much higher than the numbers used. In
addition, CHF could have substantial repercussions on an
individual’s life which were not captured by the model. The model
assumed that individuals were otherwise healthy, but the addition of
co-morbidities or co-infection with other pathogens such as the
human immunodeficiency virus (HIV) could worsen outcomes for
individuals infected with T. cruzi. Moreover, our model did not
consider how the vaccine may reduce the transmission of T. cruzi by
reducing available human hosts. The risk of infection may be higher
than reported, as many cases go undiagnosed. Our range of
infection probabilities came from Global Health Statistics reports
but may not include regions and populations with higher risk
[2,25,27]. Some studies have reported the direct progression from
acute to chronic disease as well as sudden death due to cardiac
complications during the indeterminate phase; however, these
possibilities were difficult to measure accurately and therefore not
incorporated into the model parameters [5].
Limitations
All computer models are simplifications of real world scenarios
and therefore cannot capture all possible outcomes of Chagas
disease or the efficacy of concurrent existing regional control
methods. Our model focuses on the individual rather than a
population and therefore, does not explicitly represent herd
immunity. However, increasing herd immunity could decrease
Chagas risk, and our study demonstrates how changes in Chagas
disease risk would affect the vaccine’s economic value. Addition-
ally, this model cannot account for the variation in high risk
exposure resulting from factors such as environmental conditions
or individual behaviors across Latin America. Although model
assumptions and data inputs were drawn from an extensive review
of the literature, sources may vary in quality and input values may
not hold under all conditions.
Conclusion
Our model suggests that introducing a T. cruzi vaccine to Latin
America would provide economic value. Such a vaccine could be
highly cost-effective and many cases could be economically
dominant, providing both cost savings and health benefits. Even
a vaccine with fairly low efficacy (25%) can provide cost savings.
Moreover, a vaccine could be cost-effective even at relatively low
infection risks (1%). Such findings support continued efforts to
develop a human vaccine against T. cruzi to help reduce the
significant burden of Chagas disease.
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